Free Trial
→ $30 stock to buy before Starlink goes public (WATCH NOW!) (From Paradigm Press) (Ad)tc pixel Free VRAYQ Stock Alerts

ViewRay (VRAYQ) Competitors

Compare

VRAYQ vs. SDCCQ, TTOO, WOK, AFIB, and UTRS

Should you be buying ViewRay stock or one of its competitors? The main competitors of ViewRay include SmileDirectClub (SDCCQ), T2 Biosystems (TTOO), WORK Medical Technology Group (WOK), Acutus Medical (AFIB), and Minerva Surgical (UTRS). These companies are all part of the "medical equipment" industry.

How does ViewRay compare to SmileDirectClub?

SmileDirectClub (NASDAQ:SDCCQ) and ViewRay (NASDAQ:VRAYQ) are both small-cap medical companies, but which is the better stock? We will contrast the two companies based on the strength of their dividends, profitability, earnings, media sentiment, valuation, analyst recommendations, risk and institutional ownership.

In the previous week, SmileDirectClub's average media sentiment score of 0.00 equaled ViewRay'saverage media sentiment score.

Company Overall Sentiment
SmileDirectClub Neutral
ViewRay Neutral

0.1% of SmileDirectClub shares are owned by institutional investors. Comparatively, 15.5% of ViewRay shares are owned by institutional investors. 64.7% of SmileDirectClub shares are owned by insiders. Comparatively, 2.5% of ViewRay shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.

SmileDirectClub has higher revenue and earnings than ViewRay. SmileDirectClub is trading at a lower price-to-earnings ratio than ViewRay, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
SmileDirectClub$470.74M0.00-$86.40M-$0.29N/A
ViewRay$102.21M0.00-$107.33M-$0.31N/A

SmileDirectClub has a beta of 1.39, suggesting that its stock price is 39% more volatile than the S&P 500. Comparatively, ViewRay has a beta of 0.9, suggesting that its stock price is 10% less volatile than the S&P 500.

Company Net Margins Return on Equity Return on Assets
SmileDirectClubN/A N/A N/A
ViewRay N/A N/A N/A

Summary

SmileDirectClub beats ViewRay on 5 of the 7 factors compared between the two stocks.

How does ViewRay compare to T2 Biosystems?

T2 Biosystems (NASDAQ:TTOO) and ViewRay (NASDAQ:VRAYQ) are both small-cap medical companies, but which is the better stock? We will contrast the two companies based on the strength of their dividends, profitability, earnings, media sentiment, valuation, analyst recommendations, risk and institutional ownership.

In the previous week, T2 Biosystems' average media sentiment score of 0.00 equaled ViewRay'saverage media sentiment score.

Company Overall Sentiment
T2 Biosystems Neutral
ViewRay Neutral

23.2% of T2 Biosystems shares are owned by institutional investors. Comparatively, 15.5% of ViewRay shares are owned by institutional investors. 0.0% of T2 Biosystems shares are owned by insiders. Comparatively, 2.5% of ViewRay shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.

T2 Biosystems has higher earnings, but lower revenue than ViewRay. T2 Biosystems is trading at a lower price-to-earnings ratio than ViewRay, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
T2 Biosystems$7.68M0.00-$50.08M-$3.89N/A
ViewRay$102.21M0.00-$107.33M-$0.31N/A

T2 Biosystems has a beta of 8.16, suggesting that its stock price is 716% more volatile than the S&P 500. Comparatively, ViewRay has a beta of 0.9, suggesting that its stock price is 10% less volatile than the S&P 500.

ViewRay has a net margin of 0.00% compared to T2 Biosystems' net margin of -563.16%.

Company Net Margins Return on Equity Return on Assets
T2 Biosystems-563.16% N/A -174.06%
ViewRay N/A N/A N/A

Summary

ViewRay beats T2 Biosystems on 5 of the 9 factors compared between the two stocks.

How does ViewRay compare to WORK Medical Technology Group?

WORK Medical Technology Group (NASDAQ:WOK) and ViewRay (NASDAQ:VRAYQ) are both small-cap medical companies, but which is the superior business? We will contrast the two companies based on the strength of their valuation, media sentiment, earnings, profitability, analyst recommendations, risk, institutional ownership and dividends.

15.5% of ViewRay shares are owned by institutional investors. 2.5% of ViewRay shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.

Company Net Margins Return on Equity Return on Assets
WORK Medical Technology GroupN/A N/A N/A
ViewRay N/A N/A N/A

WORK Medical Technology Group has a beta of 2.37, meaning that its stock price is 137% more volatile than the S&P 500. Comparatively, ViewRay has a beta of 0.9, meaning that its stock price is 10% less volatile than the S&P 500.

In the previous week, WORK Medical Technology Group had 2 more articles in the media than ViewRay. MarketBeat recorded 2 mentions for WORK Medical Technology Group and 0 mentions for ViewRay. WORK Medical Technology Group's average media sentiment score of 1.00 beat ViewRay's score of 0.00 indicating that WORK Medical Technology Group is being referred to more favorably in the media.

Company Overall Sentiment
WORK Medical Technology Group Positive
ViewRay Neutral

WORK Medical Technology Group has higher earnings, but lower revenue than ViewRay.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
WORK Medical Technology Group$9.81M0.00-$1.07MN/AN/A
ViewRay$102.21M0.00-$107.33M-$0.31N/A

Given ViewRay's higher probable upside, analysts clearly believe ViewRay is more favorable than WORK Medical Technology Group.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
WORK Medical Technology Group
1 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
1.00
ViewRay
0 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
0.00

Summary

WORK Medical Technology Group beats ViewRay on 5 of the 9 factors compared between the two stocks.

How does ViewRay compare to Acutus Medical?

Acutus Medical (NASDAQ:AFIB) and ViewRay (NASDAQ:VRAYQ) are both small-cap medical companies, but which is the superior business? We will contrast the two companies based on the strength of their valuation, media sentiment, earnings, profitability, analyst recommendations, risk, institutional ownership and dividends.

56.9% of Acutus Medical shares are held by institutional investors. Comparatively, 15.5% of ViewRay shares are held by institutional investors. 5.2% of Acutus Medical shares are held by company insiders. Comparatively, 2.5% of ViewRay shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.

ViewRay has a net margin of 0.00% compared to Acutus Medical's net margin of -272.74%. ViewRay's return on equity of 0.00% beat Acutus Medical's return on equity.

Company Net Margins Return on Equity Return on Assets
Acutus Medical-272.74% -311.64% -11.57%
ViewRay N/A N/A N/A

Acutus Medical has a beta of 6.03, meaning that its share price is 503% more volatile than the S&P 500. Comparatively, ViewRay has a beta of 0.9, meaning that its share price is 10% less volatile than the S&P 500.

In the previous week, Acutus Medical's average media sentiment score of 0.00 equaled ViewRay'saverage media sentiment score.

Company Overall Sentiment
Acutus Medical Neutral
ViewRay Neutral

Acutus Medical has higher earnings, but lower revenue than ViewRay. Acutus Medical is trading at a lower price-to-earnings ratio than ViewRay, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Acutus Medical$7.16M0.00-$81.66M-$0.11N/A
ViewRay$102.21M0.00-$107.33M-$0.31N/A

Summary

Acutus Medical and ViewRay tied by winning 5 of the 10 factors compared between the two stocks.

How does ViewRay compare to Minerva Surgical?

Minerva Surgical (NASDAQ:UTRS) and ViewRay (NASDAQ:VRAYQ) are both small-cap medical companies, but which is the superior business? We will contrast the two companies based on the strength of their valuation, media sentiment, earnings, profitability, analyst recommendations, risk, institutional ownership and dividends.

Minerva Surgical has higher earnings, but lower revenue than ViewRay.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Minerva Surgical$51.69M0.00-$34.11M-$4.21N/A
ViewRay$102.21M0.00-$107.33M-$0.31N/A

Minerva Surgical has a beta of 2.92, meaning that its share price is 192% more volatile than the S&P 500. Comparatively, ViewRay has a beta of 0.9, meaning that its share price is 10% less volatile than the S&P 500.

15.5% of ViewRay shares are held by institutional investors. 8.5% of Minerva Surgical shares are held by company insiders. Comparatively, 2.5% of ViewRay shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.

Company Net Margins Return on Equity Return on Assets
Minerva SurgicalN/A N/A N/A
ViewRay N/A N/A N/A

In the previous week, Minerva Surgical had 1 more articles in the media than ViewRay. MarketBeat recorded 1 mentions for Minerva Surgical and 0 mentions for ViewRay. Minerva Surgical's average media sentiment score of 0.00 equaled ViewRay'saverage media sentiment score.

Company Overall Sentiment
Minerva Surgical Neutral
ViewRay Neutral

Summary

Minerva Surgical beats ViewRay on 5 of the 8 factors compared between the two stocks.

Get ViewRay News Delivered to You Automatically

Sign up to receive the latest news and ratings for VRAYQ and its competitors with MarketBeat's FREE daily newsletter.

Subscribe Now
SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding VRAYQ and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

VRAYQ vs. The Competition

Export
MetricViewRayElectromedical equipment IndustryMedical SectorNASDAQ Exchange
Market Cap$18K$65.09M$6.25B$11.87B
Dividend YieldN/AN/A2.73%5.21%
P/E Ratio0.005.7429.0428.47
Price / SalesN/A210.89476.6160.94
Price / CashN/A41.3627.6236.52
Price / BookN/A6.059.676.67
Net Income-$107.33M-$5.50M$3.55B$332.53M

ViewRay Competitors List

Export
CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
VRAYQ
ViewRay
N/AN/AN/AN/A$18K$102.21MN/A300
SDCCQ
SmileDirectClub
N/A$0.00
-90.0%		N/AN/A$40K$470.74MN/A2,700
TTOO
T2 Biosystems
N/A$0.00
+40.0%		N/AN/A$15K$7.68MN/A180
WOK
WORK Medical Technology Group
N/A$1.37
+0.5%		N/AN/A$14K$9.81MN/A226
AFIB
Acutus Medical
N/A$0.00
flat		N/AN/A$9K$7.16MN/A340

Related Companies and Tools

Related Companies
Top 10 Stock Comparisons

This page (NASDAQ:VRAYQ) was last updated on 5/5/2026 by MarketBeat.com Staff.
From Our Partners
Iran's New Leader Just Said Something That Should Terrify Every American
Iran's Supreme Leader has declared the Strait of Hormuz closed as leverage against the U.S. - and with 40% of ...
American Alternative | Sponsoredtc pixel
Your book attached
Your Download Link (Expiring) If you still haven't downloaded the free Simple Options Trading For Beginners...
Profits Run | Sponsoredtc pixel
My feud with Zohran Mamdani
Emmy-winning analyst releases his next big story Whitney Tilson shocked the nation on 60 Minutes when he ac...
Stansberry Research | Sponsoredtc pixel
The $1.75T "Backdoor" ticker (NOT Starlink)
When the SpaceX IPO launches, most investors will already be too late. The real opportunity isn't the IPO itse...
Behind the Markets | Sponsoredtc pixel
Sell 99% of Your Stocks, Do THIS Instead…
Millionaire Trader Exposes: "The Single Stock Income Plan" With over 6,000 stocks on the market to choose ...
The Oxford Club | Sponsoredtc pixel
Trade this between 9:30 and 10:45 am EST
The first 75 minutes of the trading day may be the most overlooked window for consistent opportunities.If you ...
Base Camp Trading | Sponsoredtc pixel
Iran War Shock: What I Was Told In That Private Meeting
You’re Being LIED To About The Iran War Forget EVERYTHING you’ve heard about the Iran war. Especially th...
Banyan Hill Publishing | Sponsoredtc pixel
Elon Unveils AI Passive Income Stream for Millions of Americans
During Tesla's last earnings call, Elon Musk outlined a new AI-driven approach he says could generate $30,000-...
InvestorPlace | Sponsoredtc pixel